Nebivolol: A review

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 4, 2004, Pages 893-899

  Cockcroft, John ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

blocker; Arterial stiffness; Hypertension; Nebivolol; Nitric oxide

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ARGININE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; METOPROLOL; N(G) METHYLARGININE; NEBIVOLOL; NIFEDIPINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PLACEBO; TRIACYLGLYCEROL;

BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLD LIMB; COUGHING; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG FECES LEVEL; DRUG METABOLISM; DRUG URINE LEVEL; DYSPNEA; ESSENTIAL HYPERTENSION; FATIGUE; HEART INFARCTION; HEART OUTPUT; HEART STROKE VOLUME; HUMAN; IMPOTENCE; ORTHOSTATIC HYPOTENSION; REVIEW; RISK FACTOR; STEADY STATE; SYSTOLIC BLOOD PRESSURE; VASCULAR RESISTANCE;

ADRENERGIC BETA-ANTAGONISTS; BENZOPYRANS; ENDOTHELIUM, VASCULAR; ETHANOLAMINES; HUMANS; HYPERTENSION; NITRIC OXIDE; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; VASODILATOR AGENTS;

EID: 1842832767     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.4.893     Document Type: Review

References (64)

1. STAESSEN J, WANG J-G, THIJS L: Cardiovascular prevention and blood pressure reduction: A quantitative overview updated until March 2003. Hypertension (2003) 21:1055-1076.
2. TURNBULL F, BLOOD PRESSURE LOWERING TREATMENT TRIALIST'S COLLABORATION: Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials. Lancet (2003) 362:1527-1535.
3. WILKINSON IB, QASEM A, MCENIERY CM, WEBB DJ, AVOLIO AP, COCKCROFT JR: Nitric oxide regulates local arterial distensibility in vivo. Circulation (2002) 105:213-217.
4. KINLAY S, CREAGER MA, FUKUMOTO M et al.: Endothelium-derived nitric oxide regulates arterial elasticity in human arteries in vivo. Hypertension (2001) 38:1049-1053.
5. COCKCROFT JR, CHOWIENCZYK PJ, BRETT SE et al.: Nebivolol vasodilates human forearm vasculature: Evidence for an L-arginine/NO-dependent mechanism. J. Pharmacol. Exp. Ther. (1995) 274:1067-1071.
6. CLEOPHAS TJ, VAN OUWERKERK B, VAN DER MEULEN J: Nebivolol, a third generation novel beta-blocker, systematic review. J. Am. Coll. Ang. (2003) 1:101-113.
7. TADDEI S, VIRDIS A, GHIADONI L, SALVETTI A: The role of endothelium in human hypertension. Curr. Opin. Nephrol. Hypertens. (1996) 7:203-209.
8. TZEMOS N, LIM PO, MACDONALD TM: Nebivolol reverses endothelial dysfunction in essential hypertension. Circulation (2001) 104:511-514.
9. VAN MERODE T, VAN BORTEL LMAB, SMEETS FA: Verapamil and nebivolol improve carotid artery distensibility in hypertensive patients. J. Hypertens. (1989) 7(Suppl.):S262-S263.
10. UHLIR O, FEJIFUSA M, HAVRANEK K: Nebivolol versus metoprolol in the treatment of hypertension. Drug Investigation (1991) 3(Suppl. 1):107-110.
11. DE CREE J, GEUKENS H, VERHAEGEN H: Non-invasive cardiac haemodynamics of nebivolol. Drug Investigation (1991) 3(Suppl. 1):25-30.
12. STOLERU L, WIJNS W, VAN EYLL C, BOUVY T, VAN NUETEN L, POULEUR H: Effects of d-nebivolol and l-nebivolol on left ventricular systolic and diastolic function: Comparison with dl-nebivolol and atenolol. J. Cardiovasc. Pharmacol. (1993) 22:183-190.
13. ROBERTSON JIS, BALL SG: Hypertension for the clinician. Robertson JIS, Ball SG (Eds), WB Saunders, London, UK (1994) ISBN: 0702018120.
14. MONCADA S: Nitric oxide. J. Hypertens. (1994) 12(Suppl. 10):35-39.
15. VAN BORTEL L MAB, DE HOON JNJM, KOOL MJ, WIJNEN JA, VERTOMMEN C, VAN NUETEN L: Pharmacological properties of nebivolol in man. Eur. J. Clin. Pharmacol. (1997) 51:379-384.
16. CLEOPHAS T J: Experimental evidence of selective antagonistic action of nebivolol on beta-1 adrenergic receptors. J. Clin. Med. (1998) 2:2-8.
17. VAN NAETEN L, DE CREE J: Nebivolol: a comparison of the effects of dl-nebivolol, d-nebivolol, 1-nebivolol, atenolol, placebo on exercise-induced increases in heart rate and systolic blood pressure. Cardiovasc. Drugs Ther. (1998) 12:339-344.
18. VAN PEER A, SNOECK E, WOESTENBORGHS R: Clinical pharmacokinetics of nebivolol: A review. Drug Investigation (1991) 3(Suppl. 1):25-30.
19. HIMMELMAN A, HEDNER T, SNOECK E: Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients. Eur. J. Clin. Pharmacol. (1996) 51:259-264.
20. MONCADA S, HIGGS A: The L-arginine-nitric oxide pathway. N. Engl. J. Med. (1993) 329:2202-2212.
21. PANZA JA, CASINO PR, KILCOYNE CM, QUYYUMI AA: Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation with essential hypertension. Circulation (1993) 87:1468-1474.
22. SHIMOKAWA H: Endothelial dysfunction in hypertension. J. Atheroscler. Thromb. (1998) 4:118-127.
23. NAPOLI C, LIGUORI A, DE NIGRIS F: Beneficial effects of nebivolol on the NO-pathway in essential hypertensive patients. Eur. Heart J. (2002) 23(Suppl. 1):210 (Abstract).
24. GAO Y, NAGAO T, BOND RA, JANSSENS WJ, VANHOUTTE P: Nebivolol induces endothelium-dependent relaxations of canine coronary arteries. J. Cardiovasc. Pharmacol. (1991) 17:964-969.
25. DAWES M, BRETT SE, CHOWIENCZYK PJ, MANT TGK, RITTER JM: The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension. J. Clin. Pharmacol. (1999) 48:460-463.
26. BOWMAN AJ, CHEN CP-H, FORD GA: Nitric oxide mediated venodilator effects of nebivolol. Br. J. Clin. Pharmacol. (1994) 38:199-204.
27. RITTEE JM: Nebivolol: endothelium-mediated vasodilating effect. J. Cardiovasc. Pharmacol. (2001) 38(Suppl. 3):S13-S16.
28. VAN DE WATER A, JANSSENS WJ, VAN NUETEN L et al.: Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent and selective beta1-adrenergic antagonist. J. Cardiovasc. Pharmacol. (1988) 11:552-563.
29. VAN BORTEL L MAB, BREED JGS et al.: Nebivolol in hypertension: A double-blind placebo-controlled multicenter study assessing its antihypertensive efficacy and impact on quality of life. J. Cardiovasc. Pharmacol. (1993) 21:856-862.
30. VAN NUETEN L, DUPONT AG, VERTOMMEN C, GOYVAERTS H, ROBERTSON JIS: A dose-response trial of nebivolol in essential hypertension. J. Hum. Hypertens. (1997) 11:139-144.
31. VAN NUETEN L, SCHELLING A, VERTOMMEN C, DUPONT AG, ROBERTSON JIS: Nebivolol versus enalapril in the treatment of essential hypertension: A double-blind randomised trial. J. Hum. Hypertens. (1997) 11:813-819.
32. VAN NUETEN L, LACOURCIERE Y, VYSSOULIS G et al.: Nebivolol versus nifedipine in the treatment of essential hypertension: A double-blind randomised comparative trial. Am. J. Ther. (1998) 5:237-243.
33. VAN NUETEN L, TAYLOR FR, ROBERTSON JIS: Nebivolol versus atenolol and placebo in essential hypertension: A double-blind randomised trial. J. Hum. Hypertens. (1998) 12:135-140.
34. KAMP O, SIESWERDA GT, VISSER CA: Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am. J. Cardiol. (2003) 92:344-348.
35. VAN BORTEL L MAB, VAN BAAK MA: Exercise tolerance with nebivolol and atenolol. Cardiovasc. Drugs Ther. (1992) 6:239-247.
36. MAZZA A, GIL-EXTREMERA B, MALDONATO A, TOUTOUZAS T, PESSINA C: Nebivolol versus amlodipine as first-line treatment of essential arterial hypertension in the elderly. Blood Press. (2002) 11:182-188.
37. UKPDS GROUP: Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes (UKPDS 38). Br. Med. J. (1998) 317:703-713.
38. KANNEL WB, WILSON PW, ZHANG TJ: The epidemiology of impaired glucose tolerance and hypertension. Am. Heart J. (1991) 121:1268-1273.
39. FOGARI R, ZOPPI A, LAZZARI P et al.: Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive patients with Type II diabetes. J. Hum. Hypertens. (1997) 11:753-757.
40. CLEOPHAS TJ, GRABOWSKY I, NIEMEYER MG, MAKEL WN, VAN DER WALL EE: Long-term efficacy of nebivolol monotherapy in patients with hypertension. Curr. Ther. Res. (2001) 62:451-461.
41. FALLOIS JV, FAULHABER H-D: Nebivolol, a third generation beta blocker: The current treatment of arterial hypertension. Praxis (2001) 90:435-441.
42. LACOURCIERE Y, ARNOTT W: Placebo-controlled comparison of the effects of nebivolol and low-dose hydrochlorothiazide as monotherapies and in combination on blood pressure and lipid profile in hypertensive patients. J. Hum. Hypertens. (1994) 8:283-288.
43. BENETOS A,ASAFAR M, RUDNICHI A et al.: Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension (1997) 30:1410-1415.
44. BENETOS A, RUDNICHI A, SAFAR M, GUIZE L: Pulse pressure and cardiovascular mortality in normotensive and hypertensive subjects. Hypertension (1998) 32:560-564.
45. MITCHELL GF, MOYE L A, BRAUNWALD E et al.: Sphygomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. Circulation (1997) 96:4254-4260.
46. MILLAR JA, LEVER AF, BURKE V: Pulse pressure as a risk factor for cardiovascular events in the MRC Mild Hypertension Trial. J. Hypertens. (1999) 17:1065-1072.
47. BLACHER J, STAESSEN J, GIRERD X et al.: Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch. Intern. Med. (2000) 160:1085-1089.
48. BOUTOUYRIE P, TROPEANO AI, ASMAR R et al.: Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients. Hypertension (2002) 39:10-15.
49. CRUICKSHANK K, RISTE L, ANDERSON SG, WRIGHT JS, DUNN G, GOSLING RG: Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance. An integrated index of vascular function? Circulation (2002) 106:2085-2090.
50. BLACHER J, GUERIN AP, PANNIER B, MARCHAIS S J, SAFAR M, LONDON GM: Impact of aortic stiffness on survival in end-stage renal disease. Circulation (1999) 99:2434-2439.
51. MEAUME S, BENETOS A, HENRY OF, RUDNICHI A, SAFAR M: Aortic pulse wave velocity predicts cardiovascular mortality in subjects > 70 years of age. Arterioscler. Thromb. Vasc. Biol. (2001) 21:2046-2050.
52. COCKCROFT JR, WILKINSON IB, WEBB DJ: The Trevor Howell Lecture: Age, arterial stiffness and the endothelium. Ageing (1997) 26:53-60.
53. CHEN CP-H, TING C-T, LIN S-J et al.: Different effects of fosinipril and atenolol on wave reflection in hypertensive patients. Hypertension (1995) 25:1034-1041.
54. VAN BORTEL LMAB, KOOL MJ, BOUDIER HA, STRUIJKER HA: Effects of antihypertensive agents on local arterial distensibility and compliance. Hypertension (1995) 26:531-534.
55. BREITHAUPT-GROGLER K, LESCHINGER M, BELZ GG et al.: Influence of antihypertensive therapy with cilazapril and hydrochlorothiazide on the stiffness of the aorta. Cardiovasc. Drugs Ther. (1996) 10:49-57.
56. DREARY AJ, SCHUMANN AL, MURFET H, HAYDOCK S, FOO RS, BROWN MJ: Influence of drugs and gender on the arterial pulse wave and natiuretic peptide secretion in untreated patients with essential hypertension. Clin. Sci. (2002) 103:493-499.
57. TING C-T, YANG T-M, CHEN J-W, CHANG M-S, YIN F C P: Arterial hemodynamics in human hypertension: Effects of angiotensin converting enzyme inhibition. Hypertension (1993) 22:839-846.
58. O'ROURKE MF, KELLY RP, AVOLIO AP, HAYWARD C: Effects of arterial dilator agents on central systolic pressure and on left ventricular hydraulic load. Am. J. Cardiol. (1989) 63:381-441.
59. NICHOLS WW, O'ROURKE MF: McDonalds Blood Flow in Arteries: Theoretical, Experimental and Clinical Principles (1998).
60. MCENIERY CM, WILKINSON IB, QASEM A, AVOLIO AP, WEBB DJ, COCKCROFT JR: Nitric oxide regulates large artery stiffness in vivo. Br. J. Clin. Pharmacol. (2002) 53:426P.
61. STEINER SS, FRIEDHOFF AJ, WILSON BL, WECKER JR, SANTO JP: Antihypertensive therapy and quality of life: Comparison of atenolol, enalapril and propanolol. J. Hum. Hypertens. (1990) 4:217-225.
62. LACOURCIERE Y, LEFEBVRE J, POIRIER L: Treatment of ambulatory hypertensives with nebivolol or hydrochlorothiazide alone and in combination: A randomised, double-blind, placebo-controlled, factorial-design trial. Am. J. Hypertens. (1994) 7:137-145.
63. LACOURCIERE Y, POIRIER L, LEFEBVRE J: Comparative effects of a new cardioselective beta-blocker nebivolol and nifedipine sustained-release on 24-hour ambulatory blood pressure and plasma lipoproteins. J. Clin. Pharmacol. (1992) 32:660-666.
64. CRUICKSHANK JM, PRICHARD BNC: Beta-blockers in clinical practice. Cruickshank JM, Prichard BNC (Eds), Churchill Livingstone, Edinburgh, UK (1987) ISBN: 0443029881.